DRUG SAFETY REVIEWS
This is an alphabetized list of 24 drug safety reviews conducted by Health Canada in 2013. These reviews were triggered by reports of adverse reactions, information from a foreign regulator indicating a potential concern with a drug or through findings summarized in medical and scientific literature. Some drugs are listed several times because they were the subject of more than one review. Health Canada is not planning to release these reviews unless there is “public interest.” This list, compiled by Health Canada after repeated requests from the Toronto Star, is the only publicly available document that shows what drugs federal officials investigated in 2013.
Alimta Alvesco Antipsychotics Atypical (olanzapine, risperidone, aripiprazole) Benzodiazepines ByettaChampix Cymbalta Fluoroquinolones GLEEVEC Keppra Miacalcin and Calcimar Propyl-Thyracil QVAR RevlimidSensipar Seroquel Sutent Tridural Xarelto Zemuron Zometa Vascular Endothelial Growth Factor Inhibitors (bevacizumab, ranibizumab, sunitinib, sorafenib, axitinib, pazopanib, regorafenib, vandetanib) * ROUTINE MONITORING DEVIEWS
This is an alphabetized list of 81 brand-name drugs currently on the market that were the subject of routine safety monitoring reviews by Health Canada in 2013. According to Health Canada, this group of drug reviews will not be subject to public release. The information, including adverse drug reaction reports and usage data, is provided by manufacturers “with the understanding that this information is proprietary,” a Health Canada spokeswoman said. A senior medical adviser at Health Canada also noted the material offers only a “point-in-time” snapshot of a drug’s performance and could be taken out of context if released on its own. An additional 47 drugs were reviewed in this same manner but their names do not appear in this list because they have not yet been approved for sale in Canada.
Abilify Aclasta Adempas